ABT-702
ABT-702 is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 shows analgesic and anti-inflammatory effects in vivo. ABT-702 can be used for diabetic retinopathy research[1][2][3].
Product Specifications
CAS Number
214697-26-4
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Adenosine Kinase; Adenosine Receptor
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Neurological Disease; Inflammation/Immunology
Purity
99.61
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
BrC1=CC=CC(C2=C3C(N)=NC=NC3=NC(C4=CC=C(N5CCOCC5)N=C4)=C2)=C1
Molecular Formula
C22H19BrN6O
Molecular Weight
463.33
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
FGFR4 Recombinant Antibody, PE-Cy7 Conjugated
FGFR4 Recombinant Antibody, PE-Cy7 Conjugated
Adenosine A2b Receptor (ADORA2B) Rabbit Polyclonal Antibody